Early Prostate Cancer: Predicting Treatment Response

Status unconfirmed

Conditions studied: Prostate Cancer

In brief

This study will replicate/validate the risk prediction model developed for the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study in a more diverse patient population to assess generalizability of the model as well as evaluate the relative contribution of the Decipher Prostate Cancer Test and ProstateNext Test from Ambry Genetics, to the risk prediction model for estimating treatment outcomes, and thereby improve personalization of treatment options.

Key facts

Study ID

NCT03770351

Run by

University of California, Irvine

People needed

693

Starts

2017-01-01

Expected to finish

2021-07-01

Last updated by the study team

2021-04-09

Who can join

Age: 18 and older, up to 90. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• 18 - 90 years of age
• Prostate-Specific Antigen (PSA) values <50ng/ml
• Clinical stage of T1 or T2
• No evidence of metastasis or nodal involvement

You may not qualify if…

• Age 91 or greater
• Clinically locally advanced or metastatic disease
• PSA equal to or greater than 50ng/ml
• Diagnosis of malignancy (excluding squamous or basal cell carcinoma of the skin) within 3 years of diagnosis of prostate cancer

Where it is running

• University of California, Irvine — Irvine, California, United States (enrolling)
• Veterans Affair Long Beach Healthcare System — Long Beach, California, United States (enrolling)
• Cedars-Sinai Medical Center — Los Angeles, California, United States (enrolling)
• University of California, Los Angeles — Los Angeles, California, United States (enrolling)
• Veterans Affair West Los Angeles Healthcare System — West Los Angeles, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.